The price of Evolent Health Inc (NYSE: EVH) closed at $30.33 in the last session, down -5.01% from day before closing price of $31.93. In other words, the price has decreased by -$1.60 from its previous closing price. On the day, 1637328 shares were traded.
Ratios:
We take a closer look at EVH’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 16.95 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 30.75. For the most recent quarter (mrq), Quick Ratio is recorded 1.01 and its Current Ratio is at 1.01. In the meantime, Its Debt-to-Equity ratio is 0.77 whereas as Long-Term Debt/Eq ratio is at 0.76.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Oppenheimer on March 01, 2024, initiated with a Outperform rating and assigned the stock a target price of $45.
On January 03, 2024, Barclays started tracking the stock assigning a Overweight rating and target price of $39.
On December 06, 2023, JMP Securities started tracking the stock assigning a Mkt Outperform rating and target price of $37.JMP Securities initiated its Mkt Outperform rating on December 06, 2023, with a $37 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Dec 05 ’23 when Blackley Seth sold 141,000 shares for $26.54 per share. The transaction valued at 3,741,475 led to the insider holds 637,645 shares of the business.
McCarthy Daniel Joseph sold 11,000 shares of EVH for $330,000 on Nov 15 ’23. The PRESIDENT now owns 198,333 shares after completing the transaction at $30.00 per share. On Aug 15 ’23, another insider, Rafferty Emily Ann, who serves as the Chief Operating Officer of the company, sold 7,900 shares for $28.05 each. As a result, the insider received 221,595 and left with 70,897 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EVH now has a Market Capitalization of 3.64B and an Enterprise Value of 4.09B. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.78 while its Price-to-Book (P/B) ratio in mrq is 3.24. Its current Enterprise Value per Revenue stands at 2.08 whereas that against EBITDA is -164.96.
Stock Price History:
Over the past 52 weeks, EVH has reached a high of $36.70, while it has fallen to a 52-week low of $23.33. The 50-Day Moving Average of the stock is 31.90, while the 200-Day Moving Average is calculated to be 29.32.
Shares Statistics:
According to the various share statistics, EVH traded on average about 985.33K shares per day over the past 3-months and 750.38k shares per day over the past 10 days. A total of 113.89M shares are outstanding, with a floating share count of 109.55M. Insiders hold about 5.09% of the company’s shares, while institutions hold 110.28% stake in the company. Shares short for EVH as of Mar 15, 2024 were 10.81M with a Short Ratio of 10.97, compared to 11.32M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 9.49% and a Short% of Float of 11.13%.
Earnings Estimates
The company has 10 analysts who recommend its stock at the moment. On average, analysts expect EPS of $0.23 for the current quarter, with a high estimate of $0.34 and a low estimate of $0.1, while EPS last year was $0.21. The consensus estimate for the next quarter is $0.27, with high estimates of $0.37 and low estimates of $0.14.
Analysts are recommending an EPS of between $1.64 and $0.62 for the fiscal current year, implying an average EPS of $1.16. EPS for the following year is $1.63, with 10 analysts recommending between $2.4 and $1.2.
Revenue Estimates
According to 13 analysts, the current quarter’s revenue is expected to be $600.86M. It ranges from a high estimate of $605.76M to a low estimate of $595.82M. As of the current estimate, Evolent Health Inc’s year-ago sales were $427.69M, an estimated increase of 40.50% from the year-ago figure.
A total of 14 analysts have provided revenue estimates for EVH’s current fiscal year. The highest revenue estimate was $2.6B, while the lowest revenue estimate was $2.42B, resulting in an average revenue estimate of $2.47B. In the same quarter a year ago, actual revenue was $1.96B, up 25.70% from the average estimate. Based on 14 analysts’ estimates, the company’s revenue will be $2.86B in the next fiscal year. The high estimate is $3.05B and the low estimate is $2.7B. The average revenue growth estimate for next year is up 15.80% from the average revenue estimate for this year.
